BYSI News and Press, BeyondSpring Inc. From 07/08/21

NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will participate in the William Blair Biotech Focus ...

NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced it will host a Research and Development (...

BeyondSpring Inc. (BYSI) Q1 2021 Results Conference Call June 16, 2021 08:30 AM ET Company Participants Ashley Robinson - LifeSci Advisors Dr. Lan Huang - Co-Founder, Chairwoman and Chief Executive Officer Dr. Ramon Mohanlal - EVP, Research and Development and Chief Medical Officer Richard Da...

BeyondSpring (BYSI): Q1 GAAP EPS of -$0.58 misses by $0.04.As of March 31, 2021, the Company had cash and cash equivalents of $90.6M on hand.The Company believes it has sufficient cash to support its ongoing clinical programs over the next year, including its immuno-oncology pipelin...

- NDA Filed by U.S. Food and Drug Administration (FDA) and given Priority Review for plinabulin plus G-CSF for the prevention of CIN. A PDUFA date of November 30, 2021 has been assigned by the FDA - Highlighted PROTECTIVE-2 Phase 3 data at two scientific conferences –...

NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will host a conference call to report its financial ...

- Data further supports plinabulin’s fast onset of action and CIN prevention benefit in week 1 following chemotherapy - Single agent plinabulin (day 1 dose as chemotherapy), had non-inferior protection against CIN compared to pegfilgrastim (day 2 dose), while performing n...

NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced a late-breaking poster presentation o...

BeyondSpring ([[BYSI]] +4.3%) presents three abstracts reporting on data from the PROTECTIVE-2 Phase 3 clinical program of plinabulin in combination with pegfilgrastim for prevention of chemotherapy-induced neutropenia ((CIN)) at the 2021 ASCO Annual Meeting held, June 4 - 8.Poster 1: Clinica...

- Data demonstrate that combination of plinabulin and pegfilgrastim offers superior benefit for reducing the incidence and severity of febrile neutropenia (FN) and hospitalization, with better quality-of-life (QoL), compared to pegfilgrastim alone NEW YORK, June 07, 2021 (GLOBE NE...